Phaseline

Targets › CD80

CD80 (T-lymphocyte activation antigen CD80): drug programs, companies and trials

5 programs from 4 companies in 62 trials: 31 Phase 2, 18 Phase 1, 8 Phase 3, 5 Phase 4; Oncology, Genitourinary, Immunology; next expected readout Nov 2026.

Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation. Acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T-cells by acting as a ligand for the CD28 receptor which is constitutively expressed on the cell surface of T-cells. (UniProt, P33681)

Open in Phaseline: the race on CD80, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
Bristol-Myers SquibbAbatacept
T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor
CD86, CD80Phase 3Rheumatoid Arthritis; Myocarditis Acute; Polyarticular Course Juvenile Idiopathic Arthritis (JIA); Biphenotypic Acute Leukemia …Sep 2027
Bristol-Myers SquibbBelatacept
T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor
CD86, CD80Phase 3Renal Allograft Recipients; Kidney Diseases; Chronic Kidney Failure; Heart Transplantation …Dec 2032
Coya TherapeuticsCOYA 302
Low-dose IL-2 to enhance regulatory T cell function combined with abatacept (CTLA-4 Ig) to
IL2, CD80, CD86Phase 2Amyotrophic Lateral Sclerosis (ALS)Apr 2027
GI InnovationGI-102
CD80-IgG4 Fc-IL2v3 fusion protein
CD80Phase 2Cancer Survivors; Advanced Solid Tumor; Metastatic Castration-resistant Prostate Cancer (mCRPC)Apr 2027

Conditions

Rheumatoid Arthritis (4) Graft Vs Host Disease (3) Sickle Cell Disease (3) Cancer Survivors (2) Kidney Transplant (2) Alcohol Use Disorder (2) Head and Neck Squamous Cell Carcinoma (2) Advanced Solid Tumor (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) Amyotrophic Lateral Sclerosis (ALS) (1) Myocarditis Acute (1) Polyarticular Course Juvenile Idiopathic Arthritis (JIA) (1)

Modalities

small molecule (3), mixed (2)

Companies

Bristol-Myers Squibb (2) GI Innovation (1) Coya Therapeutics (1) University of Pennsylvania (1)

Related targets

CD86 (4) IL2 (1) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.